Trial Profile
OSIRIS (OSImertinib Rechallenge TKI In Subsequent line of therapy) A Phase II, Noncomparative, Open label, Multicentre, Study of AZD9291, in Patients with Locally Advanced or Metastatic EGFR mutate.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OSIRIS
- 17 Aug 2021 Planned number of patients changed from 81 to 90.
- 17 Aug 2021 New source identified and integrated European Clinical Trials Database (EudraCT2016-002555-17).
- 15 Aug 2021 Planned End Date changed to 9 Jan 2019.